



TRANSMITTAL FORM

07-05-02

EXPRESS MAIL LABEL NO.: EL953457790US

Cup 1635

Application Serial Number	09/155,708
Filing Date	April 5, 1999
First Named Inventor	Gwenyth Jane Farrar
Group Art Unit	1635
Examiner Name	Not yet assigned
Attorney Docket No.	MUR-003 (7593/4)
BATCH NO. (after allowance)	Not yet assigned
Patent No.	Not yet assigned
Issue Date	Not yet assigned

TECH CENTER 1600/2900

RECEIVED
JUL 11 2002

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <input type="checkbox"/> Formal Drawing(s) <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program <input type="checkbox"/> Amendment After Allowance <input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate) <input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) • A copy of an Office communication dated June 5, 2002 (11 pgs.)
<input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]		
<input type="checkbox"/> Petition for Extension of Time		
<input type="checkbox"/> Supplemental Information Disclosure Statement <input type="checkbox"/> Form PTO-1449 <input type="checkbox"/> Copies of IDS Citations		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input checked="" type="checkbox"/> Sequence Listing submission <input checked="" type="checkbox"/> Paper Copy (14 pages) <input checked="" type="checkbox"/> Computer Readable Copy (1 diskette) <input checked="" type="checkbox"/> Statement verifying identity of above (2 pages)		

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

Diana M. Steel
Attorney for Applicants
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110

Date: July 2, 2002
Reg. No. 43,153
Tel. No.: (617) 310-8168
Fax No.: (617) 248-7100

Express Mail No.: EL953457790US



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/155,708	04/05/1999	GWENYTH JANE FARRAR	MUR-7520	9036



7590 06/05/2002
 Festa, Hurwitz & Thibeault, LLP
 High Street Tower
 125 High Street
 Boston, MA 02110

RECEIVED

JUN 10 2002

EXAMINER


EPPS, JANET L

ART UNIT	PAPER NUMBER
----------	--------------

1635

PATENT DEPARTMENT
 FESTA, HURWITZ & THIBEAULT, LLP
 DATE MAILED: 06/05/2002

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No.

09/155,708

Applicant(s)

FARRAR ET AL.

Examiner

Janet L. Epps

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) ____ is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____
- 4) ☐ Interview Summary (PTO-413) Paper No(s). ____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☒ Other: *Notice to Comply Requirements*.

Application/Control Number: 09/155,708

Page 2

Art Unit: 1635

DETAILED ACTION

Sequence Information

1. The communication filed 7-13-2001 is not fully responsive to the Office communication mailed 2-13-2001 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

2. Since the reply appears to be bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE (1) MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).**

Any inquiry concerning this communication should be directed to Examiner **Janet L. Epps**, Art Unit **1635**, whose telephone number is (703) 308-8883.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

Application/Control Number: 09/155,708

Page 3


Art Unit: 1635

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L Epps, Ph.D. whose telephone number is 703-308-8883.

The examiner can normally be reached on M-T, Thurs-Friday 8:30AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (703)-308-0447. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-746-5143 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.


Janet L Epps, Ph.D.
Examiner
Art Unit 1635

JLE
June 4, 2002



Notice to Comply

Application No.	Applicant(s)	
09/155,708	Farrar et al.	
Examiner	Art Unit	
Janet Epps	1635	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG-29 (May-15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216


For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support


Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



RAW SEQUENCE LISTING ERROR REPORT



16 C/
163
#18
PP
11-15-01

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/155,708
Source: OIP
Date Processed by STIC: 7/25/2001

RECEIVED

NOV 13 2001

TECH CENTER 1600/2900

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)


TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 3.0 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 - 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:
<http://www.uspto.gov/web/offices/pac/checker>



RECEIVED

NOV 13 2001

Raw Sequence Listing Error Summary

TECH CENTER 1600/2900

SERIAL NUMBER: 09/ISS, 708

ERROR DETECTED

SUGGESTED CORRECTION

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 _____ Wrapped Nucleics
 _____ Wrapped Aminos
The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 _____ Invalid Line Length
The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 _____ Misaligned Amino
 _____ Numbering
The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 _____ Non-ASCII
The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 _____ Variable Length
Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 _____ PatentIn 2.0
 _____ "bug"
A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 _____ Skipped Sequences
 _____ (OLD RULES)
Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 _____ Skipped Sequences
 _____ (NEW RULES)
Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 9 _____ Use of n's or Xaa's
 _____ (NEW RULES)
Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10 _____ Invalid <213>
 _____ Response
Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 _____ Use of <220>
Sequence(s) 12 missing the <220> "Feature" and associated numeric identifiers and responses.
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 _____ PatentIn 2.0
 _____ "bug"
Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 _____ Misuse of n
n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.



RECEIVED

NOV 13 2001

TECH CENTER 1600/2900

OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/155,708

DATE: 07/25/2001

TIME: 17:01:31

Input Set : A:\PTO_VSK.txt

Output Set: N:\CRF3\07252001\I155708.raw

Does Not Comply
Corrected Diskette Needed

5 <110> APPLICANT: Farrar, Jane
6 Humphries, Peter
7 Kenna, Paul
9 <120> TITLE OF INVENTION: Genetic Suppression and Replacement
11 <130> FILE REFERENCE: MUR-003
13 <140> CURRENT APPLICATION NUMBER: US 09/155,708
C--> 14 <141> CURRENT FILING DATE: 1999-04-05
16 <150> PRIOR APPLICATION NUMBER: PCT/GB97/00929
17 <151> PRIOR FILING DATE: 1997-04-02
19 <160> NUMBER OF SEQ ID NOS: 28
21 <170> SOFTWARE: PatentIn version 3.0

ERRORED SEQUENCES

277 <210> SEQ ID NO: 8
278 <211> LENGTH: 649 *648*
279 <212> TYPE: DNA
280 <213> ORGANISM: mammalian
282 <220> FEATURE:
W--> 283 <221> NAME/KEY: n
284 <222> LOCATION: (1)..(649)
285 <223> OTHER INFORMATION: any
287 <400> SEQUENCE: 8 *ground 9*
E--> 288 ~~ccccctnntt~~ttttagcnc tgccaanaaa aaaggccagc tcacaggana antananaac
E--> 290 ccaactgctta ctggcttanc naaattaata cgactcacta tagggagacc caagcttggc
E--> 292 acatctgatg agtccgtgag gacgaaaaaa ttggtotaca gggccctatt ctataatgac
E--> 294 acctaaatgc tanagctcgc tgatcatact cnaactgtgcc ttctacttgc cagcctctn
E--> 296 ttgtttgccc ctcccccggtg ccttccttga ccttggaagg tgccactccc actgtccttt
E--> 298 cctaataaaa tgaggaaatt gcatcgatt gtctgagtaa gtgtcattct attctggggg
E--> 300 gtggggtggg gcaggacnnc aaaggggaag attgggaaat acaatancca agganctc
E--> 302 cccngggta attgcggatt nggctctnct gcttccttaa ggengaaana aacaactnng
E--> 304 ggcctnccgg gtttccccn ccnccctnt tagcngcgca ttantcgccg cgggtgttgt
E--> 306 tgttactccc cacctnaacg ctacanttgc cagcgccctaa cgccccccct tncntttctt
E--> 308 cctcctttt tencacttcc ccggtttcc cnccaancc naaatcngg

6059
↓
120
180
240
300 nos: off
360
420
480
540
600
649

Use of n and/or Xaa has been detected in the Sequence Listing.
Review the Sequence Listing to insure a corresponding
explanation is presented in the <220> to <223> fields of
each sequence using n or Xaa.

MI

155,708

2

<210> 12

<211> 20

<212> DNA

<213> Artificial sequence


see item 11 on Eva Summary Sheet

<400> 12

catcttcagc ctgggactgt

need <2207
&223>

20



VERIFICATION SUMMARY

PATENT APPLICATION: US/09/155,708

DATE: 07/25/2001

TIME: 17:01:32

Input Set : A:\PTO_VSK.txt

Output Set: N:\CRF3\07252001\I155708.raw

L:14 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:29 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1
L:34 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:36 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:48 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:50 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:52 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:62 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2
L:71 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:73 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:81 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:83 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:85 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:87 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:89 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:91 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:99 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3
L:107 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:119 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:121 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:123 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:125 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:127 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:129 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:137 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4
L:142 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:144 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:146 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:150 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:152 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:154 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:156 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:158 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:160 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:162 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:164 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:166 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:168 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:176 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5
L:181 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:183 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:185 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:191 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:193 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:195 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:197 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:199 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:201 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5



VERIFICATION SUMMARY

PATENT APPLICATION: US/09/155,708

DATE: 07/25/2001

TIME: 17:01:32

Input Set : A:\PTO_VSK.txt

Output Set: N:\CRF3\07252001\I155708.raw

L:203 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:212 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6
L:217 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:219 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:227 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:229 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:231 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:233 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:235 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:245 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:7
L:283 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:8
L:288 M:254 E: No. of Bases conflict, LENGTH:Input:60 Counted:59 SEQ:8-
M:254 Repeated in SeqNo=8
L:308 M:252 E: No. of Seq. differs, <211>LENGTH:Input:649 Found:648 SEQ:8
L:316 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:9
L:352 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:10
L:397 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:397 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:407 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:13
L:444 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:14
L:479 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:15
L:514 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:16
L:553 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:17
L:592 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:18